Skip to main content

Advertisement

Table 2 Clinical outcomes

From: A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

   Clarithromycin group (N = 27) Placebo group (N = 31) Pclarithromycin − Pcontrol
Clinical outcomes
 VGPR or better response after VCD induction No. (%, 95% CI) 12 (44.4%, 25.5–64.7%) 16 (51.6%, 33.1–69.8%)a − 7.2% (− 30.7–17.6%)c
 VGPR or better response after HDT No. (%, 95% CI) 16 (59.3%, 38.8–77.6%) 23 (74.2%, 55.4–88.1%)a − 14.9% (− 37.1–8.9%)c
 Leukapheresis 106/kg (range) 8 (2–20) 8.5 (2–18)b
 Any infection No. (%, 95% CI) 16 (59.3%, 38.8–77.6%) 18 (58.1%, 39.1–75.5%)a 1.2% (− 23.0–24.9%)c
  1. VGPR very good partial response, HDT high-dose melphalan with hematopoietic stem cell support
  2. aNot significant (Fisher’s exact test)
  3. bNot significant (Mann–Whitney test)
  4. cPclarithromycin − Pcontrol For response negative numbers indicate lower response in clarithromycin group. For infection positive number indicates higher risk of infection in clarithromycin group